Sign up to save your podcasts
Or
Share Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data
Guest: Jennie Taylor, MD
The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what questions remain about long-term use and broader applications.
View all episodes
By ReachMDGuest: Jennie Taylor, MD
The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what questions remain about long-term use and broader applications.